Literature DB >> 32055489

Surgical salvage in patients with advanced testicular cancer: indications, risks and outcomes.

Ryan W Speir1, Clint Cary1, Timothy A Masterson1.   

Abstract

The purpose of this review is to present a comprehensive and updated review of the literature and summary of the indications, risks and outcomes related to salvage, desperation and late relapse surgery for advanced testicular cancer. After completing a thorough review of the current literature, this review has attempted to provide an overview of the indications for salvage, desperation and late relapse retroperitoneal lymph node dissection (RPLND) followed by a summary of the histopathologic and clinical outcomes regarding each. Recent literature, combined with a significant contribution from historical studies suggest that while testicular cancer is a relatively uncommon malignancy overall, it represents the most common solid organ malignancy for young men. Although a significant number of men are cured with a combination of first-line treatments, the remaining men are a diverse and often challenging cohort who require the benefit of expertise to improve their outcomes. The role of surgical strategies in the salvage, desperation and late relapse settings is unquestionable, although the most important question remains who will benefit. This often requires a multi-disciplinary approach at centers specializing in this disease process in order to recognize who should get surgery, what surgery to do and how to minimize the potential morbidity associated with the operation. 2020 Translational Andrology and Urology. All rights reserved.

Entities:  

Keywords:  Testicular neoplasms; desperation retroperitoneal lymph node dissection (desperation RPLND); late relapse retroperitoneal neoplasms; retroperitoneal lymphadenectomy; salvage retroperitoneal lymph node dissection (salvage RPLND)

Year:  2020        PMID: 32055489      PMCID: PMC6995847          DOI: 10.21037/tau.2019.09.16

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


  38 in total

Review 1.  Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.

Authors:  Dimitrios Farmakis; Melina Pectasides; Dimitrios Pectasides
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

2.  Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.

Authors:  Scott E Eggener; Brett S Carver; Stacy Loeb; G Varuni Kondagunta; George J Bosl; Joel Sheinfeld
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

3.  Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers.

Authors:  P Albers; A Ganz; E Hannig; W D Miersch; S C Müller
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

4.  Cancer incidence patterns among adolescents and young adults in the United States.

Authors:  Xiaocheng Wu; Frank D Groves; Colleen C McLaughlin; Ahmedin Jemal; Jim Martin; Vivien W Chen
Journal:  Cancer Causes Control       Date:  2005-04       Impact factor: 2.506

5.  Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.

Authors:  C L Coogan; R S Foster; R G Rowland; R Bihrle; E R Smith; L H Einhorn; B J Roth; J P Donohue
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

6.  Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.

Authors:  Teng A Ong; Mathias H Winkler; Philip M Savage; Michael J Seckl; Timothy J Christmas
Journal:  BJU Int       Date:  2008-07-01       Impact factor: 5.588

7.  Surgical salvage of chemorefractory germ cell tumors.

Authors:  B R Murphy; E S Breeden; J P Donohue; J Messemer; W Walsh; B J Roth; L H Einhorn
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

8.  Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.

Authors:  O Rick; C Bokemeyer; S Weinknecht; J Schirren; T Pottek; J T Hartmann; T Braun; B Rachud; L Weissbach; M Hartmann; W Siegert; J Beyer
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.

Authors:  Clint Cary; Joseph M Jacob; Costantine Albany; Timothy A Masterson; Nasser H Hanna; Lawrence H Einhorn; Richard S Foster
Journal:  Clin Genitourin Cancer       Date:  2017-10-16       Impact factor: 2.872

10.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Authors:  S D Fosså; S P Stenning; A Gerl; A Horwich; P I Clark; P M Wilkinson; W G Jones; M V Williams; R T Oliver; E S Newlands; G M Mead; M H Cullen; S B Kaye; G J Rustin; P A Cook
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.